(MENAFN- EIN Presswire) EINPresswire/ -- The global biopharmaceutical contract manufacturing market is set to expand significantly over the next decade, rising from USD 11.23 billion in 2025 to USD 26.93 billion by 2035, reflecting a compound annual growth rate of 8.8%. This growth is primarily driven by the increasing complexity of biologics, the escalating cost of maintaining in-house capabilities, and the rapid shift toward advanced therapies including monoclonal antibodies, cell therapies, and gene-based medicines. Across key regions such as the United States, Europe, Asia-Pacific, and emerging hubs in the Middle East-particularly Saudi Arabia-demand for scalable, compliant biologics manufacturing continues to accelerate.

Explore trends before investing - request a sample report today!:-

Platform and Product Leadership

Mammalian-based expression systems are forecast to account for 72.5% of global production share in 2025. Their dominance is attributed to their superior ability to accurately replicate the structural and functional properties required for therapeutic biologics. These systems are widely used to produce monoclonal antibodies, which hold 44% of the product category market share due to their extensive application in oncology, autoimmune disorders, and infectious disease treatments.

Infrastructure Expansion and Technology Advancements

Increasing investments in biologics capacity expansion are shaping the competitive landscape. On April 14, 2025, Thermo Fisher Scientific announced the expansion of its biologics manufacturing facility in Hangzhou, China, to address rising regional demand and support the ongoing shift toward commercial-scale mRNA and viral vector capacity. In parallel, industry technology trends are accelerating production efficiencies. Sartorius' 2025 white paper reported widespread adoption of single-use bioreactors to reduce validation cycles, minimize contamination risks, and increase batch flexibility-key benefits for both emerging biotechs and large pharmaceutical enterprises.

Regulatory and Operational Challenges

Scalability challenges persist. Complex batch processes, high capital intensity, and heterogeneous regulatory environments across regions are restraining the pace of global manufacturing harmonization. The Biopharmaceutical Manufacturing and Quality Alliance noted on May 2, 2025, that quality framework alignment across markets remains fragmented, creating hurdles in cross-border process transfer. Nevertheless, the U.S. FDA's 2025 revisions to Chemistry, Manufacturing, and Controls (CMC) guidelines have improved regulatory predictability, enabling manufacturers to accelerate approval-ready production.

Regional Market Developments

United States:
The U.S. continues to lead the market, projected to grow from USD 3.95 billion in 2025 to USD 8.41 billion by 2035 at a CAGR of 7.8%, supported by its dominant biologics innovation pipeline, commercial-scale expertise, and sophisticated regulatory environment.

Asia-Pacific (China, Japan, India, South Korea):
China is expected to be the fastest-growing national market with a CAGR of 13.7%, driven by government-backed incentives and alignment of NMPA standards with global regulatory frameworks. Japan maintains stable growth tied to precision-driven manufacturing, while India strengthens its competitive position as a cost-efficient biologics hub. South Korea continues to expand high-capacity biologics manufacturing through large-scale facilities and automation-led efficiency.

Europe (Germany, United Kingdom, France):
Germany's manufacturing excellence, the UK's innovation corridor, and France's government-backed modernization investments ensure Western Europe retains a central role in biomanufacturing for global supply chains.

Click Here to Purchase the Report:-

Middle East (Saudi Arabia):
Saudi Arabia is emerging as a future biomanufacturing hub under Vision 2030, emphasizing localized production, workforce capacity building, and partnership-driven technology transfer initiatives.

Competitive Landscape and Strategic Positioning

The competitive environment is consolidating around CDMOs that offer integrated, end-to-end manufacturing services. Leading global suppliers include Lonza Group AG, Samsung Biologics, Thermo Fisher Scientific (Patheon), WuXi Biologics, Catalent Inc., Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, AGC Biologics, and Avid Bioservices. These organizations are investing in modular facility architecture, continuous processing systems, and advanced analytics to support rapid scale adjustments and multi-product flexibility.

Future Market Direction

As the biopharmaceutical pipeline continues to shift toward personalized medicine, cell-based therapies, and multi-specific antibody platforms, contract manufacturers with adaptive capacity, regulatory expertise, and advanced process development capabilities will be best positioned to support global therapeutic innovation.

Latest Healthcare Services Reports:-

Senior In-Home Care Services Market

Biosimilar Testing Services Market

Audiology Services Market

Why Choose FMI Empowering Decisions that Drive Real-World Outcomes:-

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analystsworldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries:...
Website:
LinkedIn| Twitter| Blogs | YouTube

MENAFN10112025003118003196ID1110319640